Myokardia Inc (MYOK) Director Kevin P. Starr Sells 816,326 Shares
Myokardia Inc (NASDAQ:MYOK) Director Kevin P. Starr sold 816,326 shares of Myokardia stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Myokardia Inc (NASDAQ MYOK) traded down $0.05 during trading hours on Friday, reaching $42.00. The company had a trading volume of 286,700 shares, compared to its average volume of 745,833. Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $49.55. The stock has a market cap of $1,502.91, a P/E ratio of -55.26 and a beta of 4.21.
Myokardia (NASDAQ:MYOK) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. During the same quarter in the previous year, the business earned ($0.35) EPS. Myokardia’s revenue was up 58.6% compared to the same quarter last year. research analysts predict that Myokardia Inc will post -1.62 EPS for the current year.
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Myokardia by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock valued at $10,020,000 after purchasing an additional 78,800 shares during the period. JPMorgan Chase & Co. boosted its position in Myokardia by 103.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock valued at $6,243,000 after acquiring an additional 242,408 shares in the last quarter. Wells Fargo & Company MN boosted its position in Myokardia by 2,151.7% during the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock valued at $17,887,000 after acquiring an additional 398,900 shares in the last quarter. VHCP Management II LLC bought a new stake in Myokardia during the 3rd quarter valued at approximately $11,355,000. Finally, RTW Investments LP bought a new stake in Myokardia during the 3rd quarter valued at approximately $10,882,000. Institutional investors own 63.61% of the company’s stock.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.